

Special Issue

Biomarkers in Perinatal Diseases

Message from the Guest Editor

Today's perinatal medicine uses the latest technological solutions. Its aim is to properly stratify high-risk groups, which should be subject to special supervision and care. The first breakthrough was the implementation of ultrasound diagnostics for general use, currently models are being constructed which, in addition to biophysical methods, are supplemented with biochemical and genetic parameters. Biomarkers play an increasingly important role in both screening and final diagnosis. The increasing sensitivity of laboratory methods, as well as the possibility of isolating the parameters of the uteroplacental compartment in areas available for diagnostics, such as maternal blood, vaginal secretions or after invasive diagnostics, such as amniocentesis, chorionic villus sampling, provide unprecedented opportunities to expand knowledge about the processes occurring inside the developing pregnancy. All this makes our knowledge broader and our actions more precise.

The aim of the issue is to draw attention to the usefulness of broadly understood biomarkers in clinical practice.

Guest Editor

Dr. Sebastian Kwiatkowski

Department of Obstetrics and Gynecology, Pomeranian Medical University in Szczecin, Szczecin, Poland

Deadline for manuscript submissions

closed (29 February 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/168701

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).